Neoantigen Identification
Mutations in protein coding genes of cancer cells are a source of potential neoantigens that the immune system can target. Characterization of expressed neoantigens has contributed to development of personalized cancer therapeutics. NGS has enabled the predictive selection of novel tumor antigens that can be applied to elicit a tumor-specific response.
Admera Health’s biopharma services characterize DNA and RNA across all ~20,000 genes in a tumor and matched normal sample configuration by exome sequencing and transcriptome sequencing to provide an extensive evaluation of candidate neoantigens derived from SNVs, indels, and/or fusions.
Based on Admera Health’s proprietary bioinformatics analysis method, experts provide accurate and comprehensive neoantigen detection, characterization and prioritization.
Neoantigen Identification
Mutations in protein coding genes of cancer cells are a source of potential neoantigens that the immune system can target. Characterization of expressed neoantigens has contributed to development of personalized cancer therapeutics. NGS has enabled the predictive selection of novel tumor antigens that can be applied to elicit a tumor-specific response.
Admera Health’s biopharma services characterize DNA and RNA across all ~20,000 genes in a tumor and matched normal sample configuration by exome sequencing and transcriptome sequencing to provide an extensive evaluation of candidate neoantigens derived from SNVs, indels, and/or fusions.
Based on Admera Health’s proprietary bioinformatics analysis method, experts provide accurate and comprehensive neoantigen detection, characterization and prioritization.
Why choose Admera Health for Neoantigen Detection
Potential Applications
- Advanced pipelines and integrated framework
- Comprehensive analysis ranging from neoantigen identification to peptide evaluation
- Competitive pricing and turnaround
- Extensive experience in sample sequencing with low input or FFPE
- Best-in-class neoantigen prediction algorithm
- Personalized cancer vaccine development
- Vaccine immunogenicity characterization and monitoring
Why choose Admera Health for Neoantigen Detection
- Advanced pipelines and integrated framework
- Comprehensive analysis ranging from neoantigen identification to peptide evaluation
- Competitive pricing and turnaround
- Extensive experience in sample sequencing with low input or FFPE
- Best-in-class neoantigen prediction algorithm
Potential Applications
- Personalized cancer vaccine development
- Vaccine immunogenicity characterization and monitoring
Neoantigen Technologies
DNA-seq
Bioinformatic Analysis
RNA-seq
Neoantigen Technologies
DNA-seq
Bioinformatic Analysis
RNA-seq
Project Deliverables
- Identification and ranking of neoantigens based on information such as HLA typing, MHC-binding prediction, peptide processing, similarity-to-self, similarity-to-known antigens, and immunogenicity
- Allelic fraction and gene/variant level expression
- Neoantigen screening and evaluation
Neoantigen Pipeline
Case Study
“Neoantigen Landscape of Relapsed Acute Leukemia Following Allogeneic Stem Cell Transplantation”
Abstract
INTRODUCTION: The potent graft versus leukemia (GVL) effect of allogeneic stem cell transplantation (allo-SCT) is considered as a blueprint for cellular immunotherapy. However, failure of GVL leads to relapse of underlying leukemia, the major cause of death after allo-SCT. In solid tumors, higher tumor mutation burdens are associated with better response to check point inhibitors which implies the importance of neoantigen specific T-cell functions in cancer immunity…
